QyScore®
Diagnosis and monitoring of CNS disorders (e.g., Alzheimer's, MS, Parkinson's)
Key Facts
About Qynapse
Founded in 2014 and headquartered in Paris, Qynapse operates at the intersection of neuroscience, AI, and digital health. The company has developed a regulatory-cleared (FDA, CE) software platform, QyScore®, which analyzes brain MRI scans to produce precise volumetric and white matter integrity measures, addressing a critical need for objective diagnostics in neurodegenerative diseases. With a focus on reducing misdiagnosis rates and improving patient outcomes, Qynapse targets both clinical care and pharmaceutical R&D, positioning itself as a key enabler in the precision medicine landscape for CNS disorders. Its technology is validated against gold-standard manual segmentation and leverages a large normative dataset.
View full company profile